We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

J.P. Morgan analyst Eric Joseph maintained a Buy rating on Akero Therapeutics (AKRO – Research Report) on January 27 and set a price target of $73.00. The company’s shares closed yesterday at ...

In this article, we are going to take a look at where Akero Therapeutics Inc. (NASDAQ:AKRO) stands against the other stocks. Wall Street ended the first trading day of the week on a mixed note ...

In honor of Black History Month, Apple has unveiled its 2025 Black Unity Collection of wallpapers, watch faces, and watch straps. This year’s set is “inspired by the rhythm of humanity ...

On Monday, Akero Therapeutics, Inc. (NASDAQ:AKRO) released preliminary topline week 96 results from SYMMETRY Phase 2b study evaluating the efficacy and safety of its lead product candidate ...

(RTTNews) - Akero Therapeutics, Inc. (AKRO), Monday, announced encouraging preliminary topline Week-96 results from a phase IIb trial of its investigational drug Efruxifermin in patients with ...